Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
25.04.25
14:04 Uhr
97,05 Euro
-1,75
-1,77 %
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
97,3097,4014:29
97,2597,3514:25

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:54Ipsen's elafibranor shows promise in rare liver disease primary sclerosing cholangitis1
DoIpsen Pharma: Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication225Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment optionsPatients...
► Artikel lesen
17.04.Ipsen's liver disease drug Iqirvo off to promising launch in battle with Gilead's Livdelzi8
16.04.Ipsen S.A. reports Q1 results2
16.04.Ipsen posts 11.7% Q1 sales growth, maintains 2025 guidance amid pipeline progress2
16.04.Ipsen Pharma: Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance848Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission...
► Artikel lesen
14.04.Ipsen Pharma: Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
IPSEN Aktie jetzt für 0€ handeln
08.04.Ipsen Pharma: Ipsen publishes its 2024 Universal Registration Document1
08.04.Ipsen's Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis1
02.04.Deutsche Bank raises Ipsen SA stock rating to buy, PT to EUR1226
19.03.Ipsen Pharma: Ipsen announces issuance of €500 million inaugural Rated Public Bond592Transaction follows Investment Grade ratings assignment from both S&P and Moody's PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company...
► Artikel lesen
12.03.Ipsen Pharma: Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins545PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective...
► Artikel lesen
06.03.Ipsen Pharma: Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital3
21.02.Ipsen Pharma: Ipsen S.A. publishes its 2024 consolidated financial statements2
13.02.Ipsen targets 5%+ sales growth and 30%+ margin for 2025 amid strong pipeline and launches5
13.02.Ipsen-Aktie fällt nach gemischten Ergebnissen im vierten Quartal7
13.02.Ipsen stock falls following mixed Q4 results3
13.02.Ipsen Full-year Revenue Rises1
13.02.Ipsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook3
13.02.Ipsen Pharma: Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025481FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2%...
► Artikel lesen
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1